Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
Letermovir tablets, 240 mg and 480 mg had annual sales of USD 289.5 mn in the United States (IQVIA MAT Jan-24)
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
Novel approach driven by GN Corp Japan with potentials in neurological illnesses
These programs are: Herpes simplex virus (HSV) vaccine candidate, Varicella-zoster virus (VZV) vaccine candidate and Checkpoint cancer vaccine.
The approval is for Cytomegalovirus, a type of Herpes virus
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)